1200 AVENUE OF THE AMERICAS, NEW YORK, X1
Regains Compliance with Nasdaq Minimum Bid Price Requirement
Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
Immunic, Inc. Announces 2025 Financial Results, Update on Phase 3 ENSURE Trials, and $200M Raised in Private Placement
Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Dr. Duane Nash Appointed CEO of Gliomic Therapeutics Inc.
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Investor Presentation
FY 2024
Q3
Q2
Q1
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Schedule 13D - Ownership Report